Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study.
Bladder cancer
GBD 2017
Mortality
Prevalence
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
11 Nov 2020
11 Nov 2020
Historique:
received:
22
06
2020
accepted:
04
11
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
15
5
2021
Statut:
epublish
Résumé
The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017). Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level. There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally. The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017).
METHODS
METHODS
Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level.
RESULTS
RESULTS
There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally.
CONCLUSION
CONCLUSIONS
The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.
Identifiants
pubmed: 33176751
doi: 10.1186/s12889-020-09835-7
pii: 10.1186/s12889-020-09835-7
pmc: PMC7659112
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1693Subventions
Organisme : the National Social Science Foundation of China
ID : 16BGL183
Organisme : Science and Technology Development of Shaanxi Province, China
ID : 2019SF-140
Références
World J Urol. 2019 Jan;37(1):3-13
pubmed: 30105454
Expert Opin Emerg Drugs. 2017 Jun;22(2):149-164
pubmed: 28556678
Urol Clin North Am. 2016 Feb;43(1):63-76
pubmed: 26614029
Cancer Causes Control. 2008 May;19(4):421-9
pubmed: 18188671
Int J Cancer. 2020 Feb 1;146(3):874-883
pubmed: 31107541
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
Hematol Oncol Clin North Am. 2015 Apr;29(2):177-89, vii
pubmed: 25836927
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Lancet. 2018 Nov 10;392(10159):1684-1735
pubmed: 30496102
Cancer Treat Rev. 2015 Feb;41(2):170-8
pubmed: 25498841
Lancet. 2016 May 21;387(10033):2145-2154
pubmed: 26520231
Eur Urol. 2014 Jul;66(1):59-73
pubmed: 24451595
J Urol. 2019 May;201(5):893-901
pubmed: 30676477
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Eur Urol. 2017 Mar;71(3):437-446
pubmed: 28029399
JAMA. 2011 Aug 17;306(7):737-45
pubmed: 21846855
World J Urol. 2020 Aug;38(8):1895-1904
pubmed: 31676912
Int J Urol. 2019 Jan;26(1):102-112
pubmed: 30345565
Curr Opin Urol. 2019 May;29(3):210-215
pubmed: 30855374
BJU Int. 2017 Dec;120(6):755-765
pubmed: 29168333
Can J Urol. 2008 Feb;15(1):3899-908
pubmed: 18304401